换一批
换一批Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
作者：
主题词
投药, 口服(Administration, Oral);老年人(Aged);抗肿瘤药(Antineoplastic Agents);女(雌)性(Female);人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);男(雄)性(Male);突变(Mutation);骨髓增生异常综合征(Myelodysplastic Syndromes);受体蛋白质酪氨酸激酶类(Receptor Protein-Tyrosine Kinases);星状孢子素(Staurosporine);治疗结果(Treatment Outcome);fms样酪氨酸激酶3(fms-Like Tyrosine Kinase 3)
DOI
10.1200/JCO.2010.28.9678
PMID
20733134
发布时间
2022-12-08
- 浏览30
Journal of clinical oncology
4339-45页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
